Embed Size (px)
Citation preview
December 10, 2013
Mentor: Julie Cherrington
Team:
Cindy Chang, PhD
Hobart W. Harris, MD, MPH
David M. Young, MD
Preventing Hernias Before They Happen
Vitruvian
Customer Interviews : 74
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.
Preventing hernias before they happen.
0
20
40
60
80
100
saline tissue sealant low dose MYOSEAL
high dose MYOSEAL
He
rnia
(%
)
Treatment Group
Pre-Clinical Data in Rats
Preventing hernias before they happen.
Business Model Canvas
Interviews
President of Paradigm Medical Consultants: Medical insurers do want to keep cost down but they have limited ability to force doctors to perform a treatment that prevents a hernia.
Interviews
My patients don’t develop hernias after my operations. The 10% incidence quoted in the literature just means that another surgeon must have a 20% incidence.
Quotes from Surgeons
At the VA, I don’t think we understand the extent of the problem because the hernias occur outside the usual follow up period. Often my patients are seen and fixed by another surgeon. I don’t even know it.
Business Model Canvas
???
Interviews
With strong clinical data, I think most surgeons would adopt hernia prevention. No one wants to be left behind on new and better treatments. After all, surgeons want to do the best for their patients.
Quote from Key Opinion Leader
Interview Partners
Partner Interviews
Myoseal Finance & Operations Timeline
Program2014 2015 2016
1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q
Pre-clinical
Formulation,
toxicology &
IND
enabling
studies
Clinical
Trials
Human
Resource
G&A + IP
Running
Total
Prod.Optim.($100,000)
Toxicology ($ 500,000)
$ 200,000
Phase 1/2 study over 2.5 years ($ 4 M)
Applicator ($ 800,000)
$ 600,000 $ 600,000
$ 100,000 $ 500,000 $ 500,000
$ 1.7 M $ 5.7 M $ 8.4 M
$ 300,000
$ 200,000
$ 3 M
De-risk the Technology
Change to another indication with the same product
Alter the product composition
Reimbursement
Effective team?
Attractive solution & ID of MVP
Unit economics Validated
Cash to exit
Plausible exit
Therapeutic Investment Readiness Level
Compelling clinical need + large mkt
Intellectual Property
Regulatory
![The Vitruvian Manifold: Inferring Dense Correspondences ...€¦ · The Vitruvian Manifold (a) (b) (c) Figure 1. (a) Da Vinci’s Vitruvian Man [11]. (b) The Vitruvian Manifold, as](https://img.dokumen.tips/doc/110x75/5f856f44ee31860268578952/the-vitruvian-manifold-inferring-dense-correspondences-the-vitruvian-manifold.jpg)
